Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Clinical Pediatrics
|
March 23, 2023
Effectiveness of Screening for Household Gun Ownership in an Urban Primary Care Clinic
Courtney M Winterer, John D Cowden, Kristi Williams, et al.
World Journal of Clinical Pediatrics
|
February 23, 2017
Using quality improvement methods to increase use of pain prevention strategies for childhood vaccination
Jennifer Verrill Schurman, Amanda D Deacy, Rebecca J Johnson, et al.
JAMA
|
October 6, 2011
Hospital-level compliance with asthma care quality measures at children's hospitals and subsequent asthma-related outcomes
Rustin B Morse, Matthew Hall, Evan S Fieldston, et al.
Academic Pediatrics
|
July 29, 2023
Accuracy of the Exeter Hospitalizations-Office Visits-Medical Conditions-Extra Care-Social Concerns Index for Identifying Children With Complex Chronic Medical Conditions in the Clinical Setting
Ingrid A Larson, Isabella Zaniletti, Rupal Gupta, et al.
The Journal of Infectious Diseases
|
April 23, 2020
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
Kristi Williams, Arangassery Rosemary Bastian, Robert Allen Feldman, et al.
The Journal of Infectious Diseases
|
October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months
Arabella S V Stuart, Miia Virta, Kristi Williams, et al.
The New England Journal of Medicine
|
February 15, 2023
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, et al.
Open Forum Infectious Diseases
|
September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months
Joanne M Langley, Terry M Nolan, Mika Rämet, et al.
Annals of Internal Medicine
|
February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine
Nadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Clinical Pediatrics
|
March 23, 2023
Effectiveness of Screening for Household Gun Ownership in an Urban Primary Care Clinic
Courtney M Winterer, John D Cowden, Kristi Williams, et al.
World Journal of Clinical Pediatrics
|
February 23, 2017
Using quality improvement methods to increase use of pain prevention strategies for childhood vaccination
Jennifer Verrill Schurman, Amanda D Deacy, Rebecca J Johnson, et al.
JAMA
|
October 6, 2011
Hospital-level compliance with asthma care quality measures at children's hospitals and subsequent asthma-related outcomes
Rustin B Morse, Matthew Hall, Evan S Fieldston, et al.
Academic Pediatrics
|
July 29, 2023
Accuracy of the Exeter Hospitalizations-Office Visits-Medical Conditions-Extra Care-Social Concerns Index for Identifying Children With Complex Chronic Medical Conditions in the Clinical Setting
Ingrid A Larson, Isabella Zaniletti, Rupal Gupta, et al.
The Journal of Infectious Diseases
|
April 23, 2020
Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years
Kristi Williams, Arangassery Rosemary Bastian, Robert Allen Feldman, et al.
The Journal of Infectious Diseases
|
October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months
Arabella S V Stuart, Miia Virta, Kristi Williams, et al.
The New England Journal of Medicine
|
February 15, 2023
Efficacy and Safety of an Ad26.RSV.preF-RSV preF Protein Vaccine in Older Adults
Ann R Falsey, Kristi Williams, Efi Gymnopoulou, et al.
Open Forum Infectious Diseases
|
September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months
Joanne M Langley, Terry M Nolan, Mika Rämet, et al.
Annals of Internal Medicine
|
February 15, 2021
A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study of Ad26.ZIKV.001, an Ad26-Vectored Anti-Zika Virus Vaccine
Nadine C Salisch, Kathryn E Stephenson, Kristi Williams, et al.
Page
of 4